RIGEL PHARMACEUTICALS INC short interest in 2024
In 2024, RIGEL PHARMACEUTICALS INC's disclosed short interest ran from 1.96% of shares outstanding on 12 Jan 2024 to 4.58% on 31 Dec 2024, a change of +2.62 percentage points. The year's high was 4.58% on 31 Dec 2024 and its low 1.96% on 12 Jan 2024, averaging 2.97% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.85 days on 31 Oct 2024. Full history: RIGEL PHARMACEUTICALS INC.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 1.96% (12 Jan 2024)
- End of year
- 4.58% (31 Dec 2024)
- Change
- +2.62 pp
- High
- 4.58% (31 Dec 2024)
- Low
- 1.96% (12 Jan 2024)
- Average
- 2.97%
- Highest days to cover
- 6.85 (31 Oct 2024)
- SEC filings marked
- 9
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 1.96% | 3.76 | results (8-K) |
| 31 Jan 2024 | 1.96% | 4.44 | |
| 15 Feb 2024 | 2.01% | 3.98 | |
| 29 Feb 2024 | 2.14% | 2.93 | |
| 15 Mar 2024 | 2.84% | 2.72 | 10-K filed, results (8-K) |
| 28 Mar 2024 | 2.88% | 5.46 | |
| 15 Apr 2024 | 2.96% | 2.47 | |
| 30 Apr 2024 | 3.25% | 3.11 | |
| 15 May 2024 | 3.22% | 5.21 | 10-Q filed, results (8-K) |
| 31 May 2024 | 3.01% | 4.96 | |
| 14 Jun 2024 | 2.79% | 3.59 | |
| 15 Aug 2024 | 3.21% | 4.53 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 3.33% | 6.09 | |
| 13 Sep 2024 | 2.84% | 5.60 | |
| 30 Sep 2024 | 2.63% | 1.66 | |
| 15 Oct 2024 | 4.08% | 5.58 | |
| 31 Oct 2024 | 3.76% | 6.85 | |
| 15 Nov 2024 | 2.63% | 1.13 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 2.67% | 2.74 | |
| 13 Dec 2024 | 3.61% | 2.82 | |
| 31 Dec 2024 | 4.58% | 2.06 |
See also: RIGEL PHARMACEUTICALS INC's full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.